33 related articles for article (PubMed ID: 38432058)
1. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of a dual-warhead covalent inhibitor of FGFR4.
Chen X; Li H; Lin Q; Dai S; Yue S; Qu L; Li M; Guo M; Wei H; Li J; Jiang L; Xu G; Chen Y
Commun Chem; 2022 Mar; 5(1):36. PubMed ID: 36697897
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-
Yang F; Chen X; Song X; Ortega R; Lin X; Deng W; Guo J; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Nov; 65(21):14809-14831. PubMed ID: 36278929
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
8. Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.
Chen X; Huang Y; Chen B; Liu H; Cai Y; Yang Y
Eur J Med Chem; 2024 Jan; 263():115947. PubMed ID: 37976704
[TBL] [Abstract][Full Text] [Related]
9. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
10. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
11. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
